Literature DB >> 18047598

Genetically seizure-prone or seizure-resistant phenotypes and their associated behavioral comorbidities.

Dan C McIntyre1, Krista L Gilby.   

Abstract

It was questioned whether amygdala kindling, a model of temporal lobe epilepsy, is under genetic control, and is associated with comorbid behavioral features. Initially, rats were selectively bred for speed of amygdala kindling, and, in subsequent generations, were assessed in behavioral paradigms to measure activity, emotionality, impulsivity, and learning. Clearly kindling was under genetic control, as two strains were developed to be either Fast or Slow to kindle, and each was associated with different neurological, electrophysiological and behavioral features. Behaviorally, the Fast rats appear much like humans with attention deficit hyperactivity disorder (ADHD), showing easy distraction, hyperactivity and impulsivity, compared to Slow rats.

Entities:  

Mesh:

Year:  2007        PMID: 18047598     DOI: 10.1111/j.1528-1167.2007.01398.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Seizure susceptibility and epileptogenesis in a rat model of epilepsy and depression co-morbidity.

Authors:  S Alisha Epps; Kroshona D Tabb; Sharon J Lin; Alexa B Kahn; Martin A Javors; Katherine A Boss-Williams; Jay M Weiss; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

2.  Distinct behavioral phenotypes in novel "fast" kindling-susceptible and "slow" kindling-resistant rat strains selected by stimulation of the hippocampal perforant path.

Authors:  Tomer Langberg; Ryan Dashek; Bernard Mulvey; Kimberly A Miller; Susan Osting; Carl E Stafstrom; Thomas P Sutula
Journal:  Neurobiol Dis       Date:  2015-10-20       Impact factor: 5.996

3.  Epilepsy in children with attention-deficit/hyperactivity disorder.

Authors:  Shanlee M Davis; Slavica K Katusic; William J Barbaresi; Jill Killian; Amy L Weaver; Ruth Ottman; Elaine C Wirrell
Journal:  Pediatr Neurol       Date:  2010-05       Impact factor: 3.372

Review 4.  The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsy.

Authors:  Wolfgang Löscher; Russell J Ferland; Thomas N Ferraro
Journal:  Epilepsy Behav       Date:  2017-06-23       Impact factor: 2.937

5.  Association of epilepsy and comorbid conditions.

Authors:  Michael Seidenberg; Dalin T Pulsipher; Bruce Hermann
Journal:  Future Neurol       Date:  2009-09-01

6.  Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder.

Authors:  Eduardo Pineda; J David Jentsch; Don Shin; Grace Griesbach; Raman Sankar; Andrey Mazarati
Journal:  Epilepsy Behav       Date:  2013-11-18       Impact factor: 2.937

7.  Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat.

Authors:  Grant S Goodrich; Anatoli Y Kabakov; Mustafa Q Hameed; Sameer C Dhamne; Paul A Rosenberg; Alexander Rotenberg
Journal:  J Neurotrauma       Date:  2013-07-25       Impact factor: 5.269

8.  Maturation-dependent behavioral deficits and cell injury in developing animals during the subacute postictal period.

Authors:  Lauren M Mlsna; Sookyong Koh
Journal:  Epilepsy Behav       Date:  2013-08-23       Impact factor: 2.937

9.  Loss of hippocampal neurons after kainate treatment correlates with behavioral deficits.

Authors:  Gisela H Maia; José L Quesado; Joana I Soares; Joana M do Carmo; Pedro A Andrade; José P Andrade; Nikolai V Lukoyanov
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

10.  Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study.

Authors:  I-Ching Chou; Yu-Tzu Chang; Zheng-Nan Chin; Chih-Hsin Muo; Fung-Chang Sung; Huang-Tsung Kuo; Chang-Hai Tsai; Chia-Hung Kao
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.